Skip to main content
Celltrion Pharm Inc. logo

Celltrion Pharm Inc. — Investor Relations & Filings

Ticker · 068760 ISIN · KR7068760008 KO Manufacturing
Open in API
Filings indexed 336 across all filing types
Latest filing 2021-03-26 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 068760

About Celltrion Pharm Inc.

https://www.celltrionph.com/en-us/home/…

Celltrion Pharm Inc. is a pharmaceutical company specializing in the manufacturing and supply of chemical pharmaceuticals and biosimilar products. The company's portfolio includes treatments for various conditions, with a notable focus on biosimilars for autoimmune diseases. A key product is Remsima, a biosimilar of Infliximab, indicated for treating rheumatoid arthritis, Crohn's disease, ulcerative colitis, and psoriasis. As an integral part of the global biopharmaceutical company Celltrion, Celltrion Pharm distributes its products to both domestic and international markets, contributing to the accessibility of advanced biologic therapies.

Recent filings

Filing Released Lang Actions
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) submitted to the Financial Services Commission/Korea Exchange. It details the issuance of stock options to employees, including the number of shares, exercise price, and valuation methodology. This type of disclosure regarding equity-based compensation and capital structure changes falls under the category of share issuance or capital changes.
2021-03-26 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a formal regulatory filing titled 'Audit Report Submission' (감사보고서 제출) from Celltrion Pharm. It provides the audit opinion (unqualified/proper), key financial data (assets, liabilities, revenue, profit), and details about the accounting firm. While it contains financial data, it is a standard regulatory disclosure announcement regarding the filing of the audit report rather than the full annual report document itself. Therefore, it fits the 'Report Publication Announcement' (RPA) category. FY 2020
2021-03-18 Korean
사업보고서 (2020.12)
Annual Report Classification · 100% confidence The document is a '사업보고서' (Business Report) for Celltrion Pharm, Inc. for the fiscal year 2020 (Jan 1, 2020 to Dec 31, 2020). It contains detailed financial statements, management discussion, corporate governance, and operational information. In the context of Korean financial filings (DART system), a '사업보고서' is the equivalent of an Annual Report (10-K). FY 2020
2021-03-18 Korean
주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Celltrion Pharm. It contains the agenda for the 21st Annual General Meeting, including items such as the approval of financial statements, election of directors, and remuneration limits. While it contains financial data (as part of the meeting materials), the primary purpose of the document is to provide shareholders with the necessary information and agenda for the upcoming meeting, which aligns with the definition of a Proxy Solicitation & Information Statement.
2021-03-11 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea used by companies to solicit shareholder votes for an upcoming Annual General Meeting (AGM). It contains details about the meeting date, agenda items (such as approval of financial statements), and instructions for electronic voting. While it includes financial statements, these are provided as supporting information for the proxy solicitation, not as a standalone annual report. Therefore, it is classified as a Proxy Solicitation & Information Statement.
2021-03-11 Korean
주주총회집중일개최사유신고
AGM Information Classification · 98% confidence The document is a formal regulatory filing submitted to the KRX (Korea Exchange) regarding the 'Reason for holding a General Meeting of Shareholders on a concentrated date'. It explains why the company (Celltrion Pharm) is holding its AGM on a date that coincides with other companies' meetings, citing internal scheduling constraints. Since this is a specific regulatory disclosure regarding meeting logistics rather than the meeting materials themselves or a proxy statement, it falls under the general regulatory filing category.
2021-03-11 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.